CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema

CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.

​Medical Xpress – latest medical and health news stories

Read More

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *